Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Cardiomyopathies

imatinib mesylate has been researched along with Cardiomyopathies in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aversa, F; Berrino, L; Buschini, A; Cappetta, D; Cavalli, S; Corradini, E; De Angelis, A; Falco, A; Frati, C; Galati, S; Galaverna, F; Graiani, G; Lagrasta, CAM; Madeddu, D; Mazzaschi, G; Prezioso, L; Quaini, F; Savi, M; Urbanek, K1
Annus, JK; Borbényi, Z; Marton, I; Nemes, A; Pósfai, É; Vecsei, L; Vörös, E1
Fassnacht, F; Fouret, P; Kahn, JE; Lefevre, G; Levy, V; Roumier, M; Russel, S; Varnous, S1
Binder, T; Esterbauer, H; Florian, S; Haas, OA; Müllauer, L; Sillaber, C; Sperr, WR; Valent, P1
Gawaz, M; Schreiber, K; Zuern, CS1

Other Studies

5 other study(ies) available for imatinib mesylate and Cardiomyopathies

ArticleYear
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors.
    Pharmacological research, 2018, Volume: 127

    Topics: Animals; Cardiomyopathies; Cell Death; Cells, Cultured; Dose-Response Relationship, Drug; Hemodynamics; Humans; Imatinib Mesylate; Male; Myocardium; Rats; Stem Cells

2018
WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM.
    Ideggyogyaszati szemle, 2015, May-30, Volume: 68, Issue:5-6

    Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow Neoplasms; Cardiomyopathies; Central Nervous System Diseases; Diagnosis, Differential; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infarction; Magnetic Resonance Imaging; Male; Methylprednisolone; mRNA Cleavage and Polyadenylation Factors; Neuroprotective Agents; Piperazines; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2015
Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
    Transplantation, 2015, Volume: 99, Issue:11

    Topics: Adult; Antineoplastic Agents; Biopsy; Cardiomyopathies; Fibrosis; Heart Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Magnetic Resonance Imaging; Male; mRNA Cleavage and Polyadenylation Factors; Myocardium; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome

2015
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Leukemia research, 2006, Volume: 30, Issue:9

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiomyopathies; Eosinophil Cationic Protein; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Serine Endopeptidases; Tryptases; World Health Organization

2006
Loeffler endocarditis: findings on magnetic resonance imaging.
    Heart (British Cardiac Society), 2007, Volume: 93, Issue:3

    Topics: Aged, 80 and over; Benzamides; Cardiomyopathies; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Angiography; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2007